- Home
- ATEN vs ANAB Comparison
ATEN vs ANAB Comparison
Compare ATEN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEN
- ANAB
- Stock Information
- Founded
- ATEN 2004
- ANAB 2005
- Country
- ATEN United States
- ANAB United States
- Employees
- ATEN N/A
- ANAB N/A
- Industry
- ATEN EDP Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ATEN Technology
- ANAB Health Care
- Exchange
- ATEN Nasdaq
- ANAB Nasdaq
- Market Cap
- ATEN 1.3B
- ANAB 1.0B
- IPO Year
- ATEN 2014
- ANAB 2017
- Fundamental
- Price
- ATEN $17.08
- ANAB $40.91
- Analyst Decision
- ATEN Strong Buy
- ANAB Buy
- Analyst Count
- ATEN 4
- ANAB 12
- Target Price
- ATEN $21.50
- ANAB $63.80
- AVG Volume (30 Days)
- ATEN 751.2K
- ANAB 734.2K
- Earning Date
- ATEN 11-04-2025
- ANAB 11-04-2025
- Dividend Yield
- ATEN 1.41%
- ANAB N/A
- EPS Growth
- ATEN 4.68
- ANAB N/A
- EPS
- ATEN 0.69
- ANAB N/A
- Revenue
- ATEN $284,406,000.00
- ANAB $169,467,000.00
- Revenue This Year
- ATEN $10.53
- ANAB $37.52
- Revenue Next Year
- ATEN $7.41
- ANAB N/A
- P/E Ratio
- ATEN $24.68
- ANAB N/A
- Revenue Growth
- ATEN 10.27
- ANAB 196.42
- 52 Week Low
- ATEN $13.81
- ANAB $12.21
- 52 Week High
- ATEN $21.90
- ANAB $43.31
- Technical
- Relative Strength Index (RSI)
- ATEN 47.11
- ANAB 69.33
- Support Level
- ATEN $16.63
- ANAB $33.10
- Resistance Level
- ATEN $17.49
- ANAB $43.31
- Average True Range (ATR)
- ATEN 0.45
- ANAB 3.12
- MACD
- ATEN -0.02
- ANAB 0.43
- Stochastic Oscillator
- ATEN 33.89
- ANAB 85.09
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).